Pyng Medical, Canada-based trauma and resuscitation products provider, has received CE Mark for its next generation Intraosseus Infusion device in Europe, and has received the US Food and Drug Administration (FDA) approval to market in the US.

Medical professionals have given the initial positive input for the FASTResponder product as it is easy to learn and use.

The positive feedback indicates the possibility of the commencing the Pyng Intraosseus Infusion products usage to wide applications and markets.

This expansion of market opportunity is anticipated to enhance its sales potential moving forward and will now increase marketing activity in an attempt to capture this opportunity, the company claimed.